Trevena Inc (TRVN)
Trevena, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for patients with central nervous system disorders. The company’s pipeline includes OLINVYK (oliceridine) injection, a G protein biased mu-opioid receptor ligand being developed for moderate-to-severe acute pain; TRV734, a small-molecule G protein biased MOR ligand that has completed phase I studies for moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator under development for chronic pain management. Trevena was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania. The company’s common stock trades on OTC Markets under the symbol TRVN.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Market Cap |
|---|---|---|---|---|---|---|
|
OTC-TRVN
|
Not available
|
Not available
|
Not available
|
Fair
|
0.0%
|
10.738 K
|